Peptidic foldamers: ramping up diversity
The non-specific melanocortin peptide agonist setmelanotide, which acts via the MC4R to inhibit food intake and produce weight loss, has been approved by the FDA for the treatment of proopiomelanocortin deficiency, leptin receptor deficiency and BardetBiedl syndrome
This class of medications (commonly-branded as Ozempic, Wegovy, Trulicity, Mounjaro, and more), which were initially developed to treat Type 2 diabetes, have become the weight loss method in the last half-decade, with more Americans seeking them out as a new way to lose weight, if they can access them
Taken together, this dichotomy suggests the possibility that, in patients recovering from an acute myocardial infarction (AMI), L-carnitine may have protective effects in the short-term but long-term risk-enhancing effects on atherosclerosis, particularly if administered via high-dose supplements